Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

NCT01088035 | Terminated Phase 2

• 1 other identifier: CMH 09C4
• Study Type: interventional
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase II study evaluating the feasibility of concurrent carboplatin given with focal radiation therapy in children age 12 months to \< 21 years with newly diagnosed localized ependymoma who have no or minimal residual disease post-operatively (\< 0.5 cm). The hypothesis is that utilizing carboplatin as a radiosensitizer is feasible and tolerable and may improve event-free survival (EFS) and minimize local recurrences as compared to historic controls. Following a neurosurgical resection and staging, patients who meet the eligibility criteria will receive standard fractionated radiation therapy at doses of 54 to 59.4 Gy to the primary site depending upon age. All patients will receive 35 mg/m²/day of carboplatin prior to each fraction of radiotherapy. Although significant neutropenia is not anticipated, G-CSF will be administered per study guidelines during radiation if neutropenia occurs. All patients will be followed for toxicity, response (resolution of residual disease) and event-free survival (EFS). Patients' tumor sample, blood and cerebro-spinal fluid (CSF) will also be prospectively evaluated to quantify the level of Survivin, a known inhibitor of apoptosis, via immunohistochemistry, Western Blot Analysis (in tumor tissue) and ELISA (in blood and CSF). The feasibility of obtaining these levels prospectively and in real time will be evaluated.

Conditions

Ependymoma

Keywords

Childhood ependymoma; Ependymoma; Survivin

Outcome Measures

Primary Outcomes (2)

• Measure the EFS of newly diagnosed non-metastatic ependymoma patients treated with a combination of daily carboplatin as a radiosensitizer and conformal radiotherapy.

  3 years

• Explore the tolerability, feasibility and toxicities associated with daily carboplatin as a radiosensitizer in patients with newly diagnosed non-metastatic ependymoma receiving focal fractionated radiotherapy.

  Tolerability and toxicity will be measured by documenting the toxicities associated with this treatment using the current CTCAE version 4.0. The feasibility of this therapy will be measured by observing the ability to finish therapy without delays and the ability to receive daily carboplatin and radiation in the time alloted by the study (within 4 hours) on a daily basis. Delays in therapy will be documented in an effort to define both tolerability and feasibility.

  1 year

Secondary Outcomes (6)

• Explore the overall survival (OS) in patients with newly diagnosed non-metastatic ependymoma treated with this regimen.

  3 years

• Evaluate the feasibility of quantifying Survivin expression in primary ependymoma tumor, blood and CSF samples in a prospective fashion.

  6 months

• Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and tumor histology.

  3 years

• Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and patient responses.

  3 years

• Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and survival outcomes.

  3 years

Study Arms (1)

Carboplatin

EXPERIMENTAL

Drug: Carboplatin

Interventions

Carboplatin DRUG

Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.

Carboplatin

Eligibility Criteria

• Age: 12 Months - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients must be enrolled before treatment begins.
• Patients must be ≥ 12 months and \< 22 years of age at the time of diagnosis.
• The target tumors are primary brain non-metastatic (M0) ependymomas tumors. Patients must have histologic verification of an ependymoma at diagnosis. Patients with the following world health organization (WHO) diagnoses will be eligible for this study:Ependymoma (Subtypes: cellular, papillary, clear cell and tanycytic) and Anaplastic Ependymoma
• Life expectancy of ≥ 8 weeks.
• Newly diagnosed ependymoma and must not have had any prior chemotherapy or radiotherapy.
• All patients must have:
• A pre-operative MRI scan of the brain with and without contrast. NOTE: CT scans are NOT sufficient for study eligibility since radiation therapy planning and responses will be based on MRI scans only.
• Post-operative head MRI scan with and without contrast (preferably within 72 hours post-operatively).
• Spinal MRI (T-1 weighted imaging with and without gadolinium) is required within 28 days of surgery if done post-operatively and within 14 days of surgery if done pre-operatively. For posterior fossa tumors, pre-operative MRI scans are preferred because surgically induced inflammation/blood can be difficult to distinguish from tumor.
• Lumbar CSF cytology examination obtained between 7 and 31 days following surgery.
• Adequate bone marrow function, defined as:
• Peripheral absolute neutrophil count (ANC) \>1500/μL
• Platelet count ≥ 100,000/μL (transfusion independent)
• Hemoglobin ≥ 10.0 gm/dl (may receive RBC transfusions)
• Adequate renal function defined as:

You may not qualify if:

• Prior chemotherapy or prior radiotherapy
• Patients who are pregnant or breast feeding, or patients (male or female) not employing adequate contraception. Acceptable means of birth control include IUD, oral contraceptive, subdermal implant, a condom with a contraceptive sponge or suppository or abstinence.
• Patients who are unable to undergo MR imaging
• Patients with evidence of metastatic disease on spine MRI or CSF sampling
• Patients with post-operative residual tumor \> 0.5 cm, unless a repeat surgery is performed making the residual tumor less than 1.5 cm². Note: Timing for enrollment and initiation of therapy will begin after second surgery if a repeat surgery is performed.

Sponsors & Collaborators

• Ann & Robert H Lurie Children's Hospital of Chicago: lead
• Brown University: collaborator

Study Sites (1)

Children's Memorial Hospital

Chicago, Illinois, 60614, United States

Location

MeSH Terms

Conditions

Ependymoma; Familial ependymoma

Interventions

Carboplatin

Condition Hierarchy (Ancestors)

Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals

Study Officials

• Jason Fangusaro, MD

  Ann & Robert H Lurie Children's Hospital of Chicago

  PRINCIPAL INVESTIGATOR

• Rachel Altura, MD

  Brown University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Attending

Study Record Dates

• First Submitted: March 16, 2010
• First Posted: March 17, 2010
• Study Start: April 1, 2010
• Primary Completion: January 1, 2015
• Study Completion: April 1, 2015
• Last Updated: March 2, 2015

Record last verified: 2015-02

Locations

US (1)